Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo

Translated title of the contribution: Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer

M. Lopez, L. Di Lauro, G. Viola, P. Foggi, F. Conti, S. Corsetti, D. Sergi, C. Botti, F. Di Filippo, P. Vici

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is generally small, and a wide variability exists among different subgroups of patients, depending on various patient and tumor characteristics. To select subsets of patients who will really benefit from chemotherapy, one of the possible strategy is based on multigene expression analysis. This approach is providing deeper insights into the biological heterogeneity of breast cancer, allowing to further subdivide hormone-receptor positive tumors into groups, with different clinical behavior and response to treatments. Among less expensive and better validated methods, high levels of Ki67, a routinely assessed immunohistochemical marker of cell proliferation, can suggest the use of chemotherapy in this subset of patients. Generally, regimen used should include a taxane. In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction. Among taxanes, docetaxel should be preferred because of a better therapeutic index, and a higher activity in comparison to paclitaxel. At present, reliable and accurate evaluation of histopathological and immunohistochemical factors may allow the choice of omitting adjuvant chemotherapy in patients with low risk hormone receptor positive HER2-negative breast cancer. Uncertainty still exists about chemotherapy benefit for a substantial proportion of women of this subgroup. Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.

Original languageItalian
Pages (from-to)481-488
Number of pages8
JournalClinica Terapeutica
Volume160
Issue number6
Publication statusPublished - Nov 2009

Fingerprint

Adjuvant Chemotherapy
Hormones
Breast Neoplasms
docetaxel
Taxoids
Drug Therapy
Anthracyclines
Neoplasms
Paclitaxel
Disease-Free Survival
Uncertainty
Meta-Analysis
Therapeutics
Cell Proliferation
Clinical Trials
Recurrence
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lopez, M., Di Lauro, L., Viola, G., Foggi, P., Conti, F., Corsetti, S., ... Vici, P. (2009). Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo. Clinica Terapeutica, 160(6), 481-488.

Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo. / Lopez, M.; Di Lauro, L.; Viola, G.; Foggi, P.; Conti, F.; Corsetti, S.; Sergi, D.; Botti, C.; Di Filippo, F.; Vici, P.

In: Clinica Terapeutica, Vol. 160, No. 6, 11.2009, p. 481-488.

Research output: Contribution to journalArticle

Lopez, M, Di Lauro, L, Viola, G, Foggi, P, Conti, F, Corsetti, S, Sergi, D, Botti, C, Di Filippo, F & Vici, P 2009, 'Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo', Clinica Terapeutica, vol. 160, no. 6, pp. 481-488.
Lopez M, Di Lauro L, Viola G, Foggi P, Conti F, Corsetti S et al. Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo. Clinica Terapeutica. 2009 Nov;160(6):481-488.
Lopez, M. ; Di Lauro, L. ; Viola, G. ; Foggi, P. ; Conti, F. ; Corsetti, S. ; Sergi, D. ; Botti, C. ; Di Filippo, F. ; Vici, P. / Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo. In: Clinica Terapeutica. 2009 ; Vol. 160, No. 6. pp. 481-488.
@article{8c07cd1efc284a8abacfd0f26cfbe40d,
title = "Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo",
abstract = "Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is generally small, and a wide variability exists among different subgroups of patients, depending on various patient and tumor characteristics. To select subsets of patients who will really benefit from chemotherapy, one of the possible strategy is based on multigene expression analysis. This approach is providing deeper insights into the biological heterogeneity of breast cancer, allowing to further subdivide hormone-receptor positive tumors into groups, with different clinical behavior and response to treatments. Among less expensive and better validated methods, high levels of Ki67, a routinely assessed immunohistochemical marker of cell proliferation, can suggest the use of chemotherapy in this subset of patients. Generally, regimen used should include a taxane. In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction. Among taxanes, docetaxel should be preferred because of a better therapeutic index, and a higher activity in comparison to paclitaxel. At present, reliable and accurate evaluation of histopathological and immunohistochemical factors may allow the choice of omitting adjuvant chemotherapy in patients with low risk hormone receptor positive HER2-negative breast cancer. Uncertainty still exists about chemotherapy benefit for a substantial proportion of women of this subgroup. Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.",
keywords = "Adjuvant chemotherapy, Breast cancer, Docetaxel, Hormone receptors, Taxanes",
author = "M. Lopez and {Di Lauro}, L. and G. Viola and P. Foggi and F. Conti and S. Corsetti and D. Sergi and C. Botti and {Di Filippo}, F. and P. Vici",
year = "2009",
month = "11",
language = "Italian",
volume = "160",
pages = "481--488",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6",

}

TY - JOUR

T1 - Chemioterapia adiuvante del carcinoma della mammella con recettori ormonali positivi HER2-negativo

AU - Lopez, M.

AU - Di Lauro, L.

AU - Viola, G.

AU - Foggi, P.

AU - Conti, F.

AU - Corsetti, S.

AU - Sergi, D.

AU - Botti, C.

AU - Di Filippo, F.

AU - Vici, P.

PY - 2009/11

Y1 - 2009/11

N2 - Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is generally small, and a wide variability exists among different subgroups of patients, depending on various patient and tumor characteristics. To select subsets of patients who will really benefit from chemotherapy, one of the possible strategy is based on multigene expression analysis. This approach is providing deeper insights into the biological heterogeneity of breast cancer, allowing to further subdivide hormone-receptor positive tumors into groups, with different clinical behavior and response to treatments. Among less expensive and better validated methods, high levels of Ki67, a routinely assessed immunohistochemical marker of cell proliferation, can suggest the use of chemotherapy in this subset of patients. Generally, regimen used should include a taxane. In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction. Among taxanes, docetaxel should be preferred because of a better therapeutic index, and a higher activity in comparison to paclitaxel. At present, reliable and accurate evaluation of histopathological and immunohistochemical factors may allow the choice of omitting adjuvant chemotherapy in patients with low risk hormone receptor positive HER2-negative breast cancer. Uncertainty still exists about chemotherapy benefit for a substantial proportion of women of this subgroup. Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.

AB - Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is generally small, and a wide variability exists among different subgroups of patients, depending on various patient and tumor characteristics. To select subsets of patients who will really benefit from chemotherapy, one of the possible strategy is based on multigene expression analysis. This approach is providing deeper insights into the biological heterogeneity of breast cancer, allowing to further subdivide hormone-receptor positive tumors into groups, with different clinical behavior and response to treatments. Among less expensive and better validated methods, high levels of Ki67, a routinely assessed immunohistochemical marker of cell proliferation, can suggest the use of chemotherapy in this subset of patients. Generally, regimen used should include a taxane. In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction. Among taxanes, docetaxel should be preferred because of a better therapeutic index, and a higher activity in comparison to paclitaxel. At present, reliable and accurate evaluation of histopathological and immunohistochemical factors may allow the choice of omitting adjuvant chemotherapy in patients with low risk hormone receptor positive HER2-negative breast cancer. Uncertainty still exists about chemotherapy benefit for a substantial proportion of women of this subgroup. Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Docetaxel

KW - Hormone receptors

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=75749088535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749088535&partnerID=8YFLogxK

M3 - Articolo

C2 - 20198292

AN - SCOPUS:75749088535

VL - 160

SP - 481

EP - 488

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6

ER -